Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11–12

HOS-116342 · Präparat HOS-094447

11  Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir may cause a modest decrease in on darunavir plasma darunavir plasma concentrations. concentrations does not appear to be clinically relevant. Boosted PREZISTA and raltegravir can be used without dose adjustments. Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and 400 mg once daily didanosine Cmin ND didanosine can be used without didanosine Cmax ↓ 16% dose adjustments. darunavir AUC ↔ Didanosine is to be administered darunavir Cmin ↔ on an empty stomach, thus it darunavir Cmax ↔ should be administered 1 hour before or 2 hours after boosted PREZISTA given with food. Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted tenofovir Cmax ↑ 24% PREZISTA is given in # darunavir AUC ↑ 21% combination with tenofovir # darunavir Cmin ↑ 24% disoproxil, particularly in patients # with underlying systemic or renal darunavir Cmax ↑ 16% disease, or in patients taking (↑ tenofovir from effect on MDR-1 nephrotoxic agents. transport in the renal tubules) PREZISTA co-administered with cobicistat lowers the creatinine clearance. Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted PREZISTA. Abacavir Not studied. Based on the different Boosted PREZISTA can be used Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose Lamivudine zidovudine, emtricitabine, stavudine, adjustment. Stavudine lamivudine, that are primarily renally Zidovudine excreted, and abacavir for which PREZISTA co-administered with metabolism is not mediated by CYP450, cobicistat lowers the creatinine no interactions are expected for these clearance. Refer to section 4.4 if medicinal compounds and boosted creatinine clearance is used for PREZISTA. dose adjustment of emtricitabine or lamivudine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) cobicistat (HOS-088111) creatinine (HOS-086273) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) raltegravir (HOS-086187) abacavir (HOS-088077) emtricitabine (HOS-085840)